A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Your doctor may prescribe Tivicay for the treatment of HIV-1 infection. This medication should only be prescribed by healthcare professionals trained in the management of HIV and AIDS.
Tivicay is usually not given on its own and will be given with other drugs that help to suppress HIV infection. These types of drugs are called Antiretroviral Therapy (ART).
Tivicay works by shutting off a protein in HIV viral particles called integrase. Integrase is critical for the replication of HIV after it enters a human cell.
The usual dose is 50 mg by mouth one to two times daily. The dose may be different depending on your individual circumstances.
Dolutegravir is the active ingredient in this drug.
There are many potential drug-drug interactions, including:
Tell your doctor if you have a history of skin conditions, liver problems, or have a hypersensitivity to any of the ingredients in this medication.
Tell your doctor if you have a history of hepatitis B or hepatitis C infection.
Ask your doctor and pharmacist for a full list of side effects before starting this drug.
The most common side effects of this drug include:
Buy Tivicay from Canada Pharmacy for a great price.
Tivicay [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013.